Estimates of relative risk for AML associated with various genotypes
| Genotype . | Controls . | Patients with AML . | OR (95% CI)* . | P . | Patients with t-AML . | OR (95% CI)* . | P . |
|---|---|---|---|---|---|---|---|
| XRCC1-399 | 178 | 133 | 34 | ||||
| Arg/Arg | 55 | 52 | 1.0† | — | 18 | 1.0† | — |
| Arg/Gln | 76 | 57 | 0.84 (0.50-1.42) | .52 | 12 | 0.54 (0.24-1.23) | .14 |
| Gln/Gln | 47 | 24 | 0.57 (0.30-1.08) | .09 | 4 | 0.28 (0.09-0.88) | .03 |
| Arg/Gln + Gln/Gln | 123 | 81 | 0.74 (0.46-1.20) | .22 | 16 | 0.44 (0.20-0.93) | .03 |
| XRCC3-241 | 175 | 123 | 31 | ||||
| Thr/Thr | 92 | 53 | 1.0† | — | 12 | 1.0† | — |
| Thr/Met | 64 | 53 | 1.50 (0.90-2.51) | .12 | 12 | 1.55 (0.64-3.73) | .33 |
| Met/Met | 19 | 17 | 1.49 (0.70-3.20) | .31 | 7 | 2.66 (0.89-7.94) | .08 |
| Thr/Met + Met/Met | 83 | 70 | 1.50 (0.93-2.42) | .10 | 19 | 1.82 (0.82-4.05) | .14 |
| NQO1 | 175 | 134 | 33 | ||||
| Pro/Pro | 110 | 95 | 1.0† | — | 19 | 1.0† | — |
| Pro/Ser | 53 | 30 | 0.66 (0.39-1.13) | .13 | 14 | 1.62 (0.74-3.54) | .22 |
| Ser/Ser | 12 | 9 | 0.71 (0.26-1.89) | .49 | 0 | — | — |
| Pro/Ser + Ser/Ser | 65 | 39 | 0.67 (0.41-1.10) | .11 | 14 | 1.34 (0.62-2.91) | .45 |
| XRCC1-194 | 87 | 114 | 14 | ||||
| Arg/Arg | 78 | 100 | 1.0† | — | 12 | 1.0† | — |
| Arg/Trp | 7 | 12 | 2.79 (0.77-10.05) | .12 | 2 | 0.13 (0.00-43.31) | .49 |
| Trp/Trp | 2 | 0 | — | — | 0 | — | — |
| Arg/Trp + Trp/Trp | 9 | 12 | 2.11 (0.64-6.98) | .22 | 2 | 0.12 (0.00-40.48) | .48 |
| XPD-751 | 73 | 107 | 15 | ||||
| Lys/Lys | 30 | 40 | 1.0† | — | 4 | 1.0† | — |
| Lys/Gln | 32 | 51 | 0.74 (0.31-1.77) | .50 | 8 | 9.66 (0.78-119.57) | .08 |
| Gln/Gln | 11 | 16 | 0.61 (0.18-2.04) | .42 | 3 | 1.13 (0.04-28.80) | .94 |
| Lys/Gln + Gln/Gln | 43 | 67 | 0.70 (0.31-1.58) | .39 | 11 | 5.30 (0.54-52.26) | .15 |
| Genotype . | Controls . | Patients with AML . | OR (95% CI)* . | P . | Patients with t-AML . | OR (95% CI)* . | P . |
|---|---|---|---|---|---|---|---|
| XRCC1-399 | 178 | 133 | 34 | ||||
| Arg/Arg | 55 | 52 | 1.0† | — | 18 | 1.0† | — |
| Arg/Gln | 76 | 57 | 0.84 (0.50-1.42) | .52 | 12 | 0.54 (0.24-1.23) | .14 |
| Gln/Gln | 47 | 24 | 0.57 (0.30-1.08) | .09 | 4 | 0.28 (0.09-0.88) | .03 |
| Arg/Gln + Gln/Gln | 123 | 81 | 0.74 (0.46-1.20) | .22 | 16 | 0.44 (0.20-0.93) | .03 |
| XRCC3-241 | 175 | 123 | 31 | ||||
| Thr/Thr | 92 | 53 | 1.0† | — | 12 | 1.0† | — |
| Thr/Met | 64 | 53 | 1.50 (0.90-2.51) | .12 | 12 | 1.55 (0.64-3.73) | .33 |
| Met/Met | 19 | 17 | 1.49 (0.70-3.20) | .31 | 7 | 2.66 (0.89-7.94) | .08 |
| Thr/Met + Met/Met | 83 | 70 | 1.50 (0.93-2.42) | .10 | 19 | 1.82 (0.82-4.05) | .14 |
| NQO1 | 175 | 134 | 33 | ||||
| Pro/Pro | 110 | 95 | 1.0† | — | 19 | 1.0† | — |
| Pro/Ser | 53 | 30 | 0.66 (0.39-1.13) | .13 | 14 | 1.62 (0.74-3.54) | .22 |
| Ser/Ser | 12 | 9 | 0.71 (0.26-1.89) | .49 | 0 | — | — |
| Pro/Ser + Ser/Ser | 65 | 39 | 0.67 (0.41-1.10) | .11 | 14 | 1.34 (0.62-2.91) | .45 |
| XRCC1-194 | 87 | 114 | 14 | ||||
| Arg/Arg | 78 | 100 | 1.0† | — | 12 | 1.0† | — |
| Arg/Trp | 7 | 12 | 2.79 (0.77-10.05) | .12 | 2 | 0.13 (0.00-43.31) | .49 |
| Trp/Trp | 2 | 0 | — | — | 0 | — | — |
| Arg/Trp + Trp/Trp | 9 | 12 | 2.11 (0.64-6.98) | .22 | 2 | 0.12 (0.00-40.48) | .48 |
| XPD-751 | 73 | 107 | 15 | ||||
| Lys/Lys | 30 | 40 | 1.0† | — | 4 | 1.0† | — |
| Lys/Gln | 32 | 51 | 0.74 (0.31-1.77) | .50 | 8 | 9.66 (0.78-119.57) | .08 |
| Gln/Gln | 11 | 16 | 0.61 (0.18-2.04) | .42 | 3 | 1.13 (0.04-28.80) | .94 |
| Lys/Gln + Gln/Gln | 43 | 67 | 0.70 (0.31-1.58) | .39 | 11 | 5.30 (0.54-52.26) | .15 |